10-Q: Semler Scientific's Q2 Net Income Soars on Bitcoin Gains

Semler Scientific reported a significant increase in second-quarter net income driven by Bitcoin fair value gains, despite a sharp decline in healthcare revenues and a substantial litigation settlement charge.

Summary

• Net income for the three months ended June 30, 2025, was $66.9 million, a substantial increase from $11 thousand in the same period of 2024, primarily due to an $83.8 million unrealized gain on Bitcoin holdings.
• Revenues for the three months ended June 30, 2025, decreased by 43% to $8.2 million from $14.5 million in the prior year, mainly due to decreased QuantaFlo testing volume attributed to the 2024 CMS rate announcement.
• For the six months ended June 30, 2025, revenues were $17.1 million, down 44% from $30.4 million in 2024.
• Operating expenses for the six months ended June 30, 2025, surged by 178% to $50.2 million, including a $29.8 million contingent liability for a proposed DOJ settlement.
• The company held 4,636 Bitcoins with a fair value of $496.9 million as of June 30, 2025, and increased its holdings to 5,021 Bitcoins by July 31, 2025, with an aggregate cost of $475.8 million.
• Semler Scientific raised $100.0 million through senior convertible notes and $156.9 million from at-the-market (ATM) common stock offerings during the six months ended June 30, 2025.
• A new wholly-owned subsidiary, CardioVanta, was formed to focus on early detection of heart failure and cardiac arrhythmia monitoring, aiming for a high-margin software-as-a-service (SaaS) business model.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in core healthcare revenues and operational profitability, coupled with a large one-time legal settlement. While substantial Bitcoin fair value gains boosted net income, this is a non-operational and highly volatile factor, masking underlying business challenges and risks associated with the unique treasury strategy.

Positives

• Net income for Q2 2025 significantly increased to $66.9 million, primarily driven by an $83.8 million unrealized gain on Bitcoin holdings.
• The company's total assets grew substantially to $522.6 million as of June 30, 2025, from $239.8 million at December 31, 2024, largely due to increased Bitcoin investments.
• Successful capital raises, including $100.0 million from senior convertible notes and $156.9 million from ATM common stock offerings, have bolstered liquidity and funded Bitcoin acquisitions.
• An agreement in principle has been reached for a $29.8 million settlement with the U.S. Department of Justice, potentially resolving a significant legal overhang.
• The formation of CardioVanta, a new subsidiary focused on cardiac technology with a high-margin SaaS model, indicates strategic diversification within the healthcare sector.
• The company's cash and cash equivalents increased to $13.5 million at June 30, 2025, from $8.8 million at December 31, 2024.

Negatives

• Revenues decreased significantly by 43% for the three months and 44% for the six months ended June 30, 2025, primarily due to reduced QuantaFlo usage following the 2024 CMS rate announcement.
• The company reported an operating loss of $2.053 million for the three months and $33.156 million for the six months ended June 30, 2025, compared to operating income in the prior year periods.
• A $29.8 million litigation contingency related to the proposed DOJ settlement significantly impacted operating expenses and contributed to a net loss for the six-month period before Bitcoin gains.
• Negative working capital of approximately $14.9 million as of June 30, 2025, largely due to the one-time contingent liability.
• Cash flow from operating activities was negative $1.4 million for the six months ended June 30, 2025, a significant decline from $10.6 million generated in the prior year.
• The company incurred an impairment charge of $1.1 million on its investment in Mellitus Health, Inc. in March 2025, following a previous $0.6 million charge in December 2023, indicating unsuccessful prior investments.
• High reliance on a limited number of customers, with two customers accounting for 44.9% and 31.0% of revenues for the three months ended June 30, 2025, and 45.7% and 28.1% of accounts receivable as of June 30, 2025, poses concentration risk.

Risks

• Bitcoin is a highly volatile asset, and fluctuations in its price are likely to significantly influence financial results and the market price of common stock.
• The Bitcoin treasury strategy is subject to significant legal, commercial, regulatory, and technical uncertainty, including potential reclassification of Bitcoin as a security, which could lead to classification as an investment company under the 1940 Act.
• The availability of spot Bitcoin Exchange Traded Products (ETPs) may adversely affect the market price of the company's common stock, as investors may choose ETPs for direct Bitcoin exposure.
• Exposure to counterparty risks, particularly with custodians, where custodially-held Bitcoin may become part of the custodian's insolvency estate in bankruptcy proceedings.
• Security breaches or cyberattacks on the company or its third-party service providers could lead to loss of Bitcoin or sensitive data.
• Changes in the regulatory reimbursement landscape, such as the 2024 CMS rate announcement, have negatively impacted the perceived profitability and usage of QuantaFlo, leading to decreased revenues.
• The company markets a limited number of FDA-cleared testing products, and these may not achieve broad market acceptance or commercial success.
• Reliance on a small number of key personnel and a direct sales force, the loss of whom could severely damage the business.
• The company does not require long-term licenses or maintenance contracts from customers, leading to potential loss of customers on short notice.
• Concentration of revenues and accounts receivable with a limited number of customers poses a significant risk if these relationships are disrupted.
• Reliance on a small number of independent suppliers and facilities for QuantaFlo manufacturing, with potential for delays or disruptions.
• The company's indebtedness, including $100.0 million in senior convertible notes, could limit cash flow and expose it to financial risks.
• Potential future dilution for stockholders as a result of future equity offerings.
• The company operates in an intensely competitive and rapidly changing business environment, with a substantial risk of products becoming obsolete or uncompetitive.
• Subject to various healthcare fraud and abuse laws and regulations, with ongoing risk related to the DOJ investigation if a final settlement is not reached.

Future Outlook

The company intends to strategically acquire additional Bitcoin using proceeds from equity and debt financings, as well as cash generated from operations, with a stated goal of reaching 10,000 Bitcoins by the end of 2025, 42,000 by the end of 2026, and 105,000 by the end of 2027. In its healthcare business, the company is seeking a new FDA 510(k) clearance for expanded use of QuantaFlo to aid in the diagnosis of other cardiovascular diseases, such as heart failure. The newly formed CardioVanta subsidiary plans to develop additional complementary, proprietary products and services in cardiac technology and care systems, and will seek capital from outside investors to fund its initial needs. The company believes its current sources of funds will provide adequate liquidity for the next 12 months and long-term.

Management Comments

• We are a company that has adopted Bitcoin as its primary treasury reserve asset and are one of the leading corporate holders of Bitcoin.
• We intend to strategically acquire additional Bitcoin by using proceeds from equity and debt financings, as well as cash generated from our operations.
• The primary reason for the decrease in revenues was decreased testing volume at some of our customers, which we believe is a result of the 2024 CMS rate announcement.
• Our healthcare business is our predominant operational focus, providing cash flows and enabling us to pursue our Bitcoin treasury strategy.
• We believe our current sources of funds will provide us with adequate liquidity during the 12-month period following June 30, 2025, as well as in the long-term.

Industry Context

The company operates in two distinct areas: the medical device industry, specifically diagnostics for cardiovascular diseases, and the digital asset market through its Bitcoin treasury strategy. In medical devices, the industry faces ongoing pressures from healthcare cost containment and evolving reimbursement policies, as evidenced by the negative impact of the 2024 CMS rate announcement on QuantaFlo's usage. The digital asset market, particularly Bitcoin, is characterized by extreme price volatility, a rapidly evolving regulatory landscape, and increasing institutional adoption, including the recent approval of spot Bitcoin ETPs. The company's dual strategy positions it uniquely, but also exposes it to the distinct risks and trends of both sectors.

Comparison to Industry Standards

• In the medical device sector, the significant 43-44% revenue decline for QuantaFlo due to CMS reimbursement changes indicates underperformance compared to companies with stable or growing reimbursement streams for their diagnostic products. For example, companies like Abbott Laboratories or Medtronic, while diversified, typically manage reimbursement changes to mitigate such sharp revenue drops in their established product lines.
• The company's strategy of adopting Bitcoin as a primary treasury reserve asset is highly unconventional for a medical device company. While MicroStrategy (MSTR) has famously pursued a similar Bitcoin-centric treasury strategy, Semler Scientific's approach is unique in combining this with an operational healthcare business. This makes direct comparison to traditional industry standards difficult, as its financial performance is now heavily influenced by Bitcoin's volatile price movements, unlike most peers in either the medical device or traditional corporate sectors.
• The company's goal to accumulate 105,000 Bitcoins by the end of 2027 is an aggressive target, positioning it to potentially become one of the largest corporate holders of Bitcoin, comparable in ambition to MicroStrategy's ongoing accumulation strategy, which has seen its Bitcoin holdings grow to over 200,000 BTC.

Corporate Governance

Legal Proceedings

• The company has reached an agreement in principle to pay $29.8 million to settle all claims related to a U.S. Department of Justice (DOJ) civil investigative demand (excluding potential relators' counsel fees).
• There is no guarantee that a final agreement will be reached with the DOJ or the Department of Health and Human Services (HHS), and failure to do so could result in the DOJ filing a civil False Claims Act lawsuit seeking damages in excess of the agreed settlement amount.
• The company intends to vigorously defend itself if a complaint is filed by the DOJ.

Stakeholder Impact

• **Shareholders**: Experience significant volatility in stock price due to the Bitcoin treasury strategy and its impact on reported net income. Potential for dilution from ongoing ATM offerings and convertible notes. The DOJ settlement reduces a significant legal uncertainty but incurs a substantial one-time cost.
• **Customers**: Decreased usage of QuantaFlo due to CMS reimbursement changes negatively impacts healthcare providers' perceived profitability, potentially leading to reduced adoption or cancellations.
• **Employees**: Higher stock-based compensation expense noted in general and administrative, and sales and marketing expenses, aligning employee interests with stockholders. However, the decline in core business revenue could impact future operational stability.
• **Creditors**: The issuance of $100.0 million in senior convertible notes increases the company's indebtedness, potentially limiting cash flow available for other purposes and increasing vulnerability to adverse economic conditions.
• **Suppliers**: Reliance on a small number of independent suppliers and manufacturing facilities for QuantaFlo creates supply chain risk, potentially impacting product availability and delivery schedules.

Next Steps

• Finalize the agreement with the U.S. Department of Justice and the Department of Health and Human Services regarding the $29.8 million settlement.
• Continue to strategically acquire additional Bitcoin, aiming for 10,000 Bitcoins by the end of 2025, 42,000 by the end of 2026, and 105,000 by the end of 2027.
• Pursue new FDA 510(k) clearance for expanded use of QuantaFlo to aid in the diagnosis of other cardiovascular diseases, such as heart failure.
• CardioVanta, the new subsidiary, will seek outside investors to validate its long-term value and fund its initial capital needs.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on condensed consolidated financial statements, with effects expected to be reflected in the three-month period ended September 30, 2025.
• Monitor and adapt to the new FASB accounting guidance on convertible debt instruments (effective after December 15, 2025) and expense disaggregation disclosures (effective after December 15, 2026).

Key Dates

Recommendation

The company presents a mixed financial picture. While the significant net income increase in Q2 2025 is impressive, it is primarily driven by non-operational Bitcoin fair value gains, which are highly volatile and subject to market fluctuations. The core healthcare business is experiencing substantial revenue declines and operating losses due to unfavorable CMS reimbursement changes, indicating fundamental operational challenges. The large DOJ settlement, while an agreement in principle, represents a significant cash outflow and ongoing legal risk if not finalized. The aggressive Bitcoin accumulation strategy introduces substantial new risks, including regulatory uncertainty and liquidity concerns. Given the strong capital raises and strategic pivot towards Bitcoin, there is potential for upside if Bitcoin prices continue to rise and the healthcare business stabilizes. However, the underlying operational weakness and the inherent volatility and regulatory risks of the Bitcoin strategy warrant a cautious 'hold' recommendation. Investors should monitor the healthcare business's ability to regain profitability and the long-term implications of the Bitcoin treasury strategy.

Keywords

Bitcoin, Healthcare Technology, Medical Devices, QuantaFlo, Cardiovascular Disease, Peripheral Arterial Disease, PAD, SEC Filing, 10-Q, Digital Assets, Treasury Strategy, Convertible Notes, ATM Offering, FDA Clearance, CMS Reimbursement, Corporate Governance, Financial Reporting